ADB-FUBINACA
http://dbpedia.org/resource/ADB-FUBINACA an entity of type: Thing
ADB-FUBINACA is a designer drug identified in synthetic cannabis blends in Japan in 2013. In 2018, it was the third-most common synthetic cannabinoid identified in drugs seized by the Drug Enforcement Administration. An analogue of ADB-FUBINACA, ADSB-FUB-187, containing a more functionalized carboxamide substituent was recently reported.
rdf:langString
rdf:langString
ADB-FUBINACA
xsd:integer
38997460
xsd:integer
1092593298
xsd:integer
21
xsd:integer
1185282
xsd:integer
29763706
xsd:integer
1
xsd:integer
23
rdf:langString
N--1--1H-indazole-3-carboxamide
rdf:langString
Anlage II
rdf:langString
Class B
rdf:langString
Schedule I
xsd:integer
4
xsd:integer
2
xsd:integer
70969086
rdf:langString
O=CC1=NNC3=C1C=CC=C3
rdf:langString
InChI=1S/C21H23FN4O2/c1-211824-2017-15-6-4-5-7-162612-13-8-10-1411-9-13/h4-11,18H,12H2,1-3H3,/t18-/m1/s1
rdf:langString
ZSSGCSINPVBLQD-GOSISDBHSA-N
xsd:integer
52350
rdf:langString
ADB-FUBINACA is a designer drug identified in synthetic cannabis blends in Japan in 2013. In 2018, it was the third-most common synthetic cannabinoid identified in drugs seized by the Drug Enforcement Administration. The (S)-enantiomer of ADB-FUBINACA is described in a 2009 Pfizer patent and has been reported to be a potent agonist of the CB1 receptor and the CB2 receptor with EC50 values of 1.2 nM and 3.5 nM, respectively. ADB-FUBINACA features a carboxamide group at the 3-indazole position, like SDB-001 and STS-135. ADB-FUBINACA appears to be the product of rational drug design, since it differs from AB-FUBINACA only by the replacement of the isopropyl group with a tert-butyl group. An analogue of ADB-FUBINACA, ADSB-FUB-187, containing a more functionalized carboxamide substituent was recently reported.
rdf:langString
Schedule II
xsd:nonNegativeInteger
6469
xsd:string
1185282-00-1
xsd:string
05235E1S2O
xsd:string
70969086